We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Ovarian Cancer Test Exhibits Exceptional Accuracy

By LabMedica International staff writers
Posted on 23 Aug 2010
A new technique correctly identified women with ovarian cancer in 100% of the patients tested using mass spectrometry analysis of one drop of blood. More...


The measurement step in the test used 200 μL of blood serum, which is vaporized by hot helium plasma. As the molecules from the serum become electrically charged, a mass spectrometer is used to measure their relative abundance.

The test looks at metabolites in the serum. Sera were obtained from 44 women with ovarian cancer, and 50 women with either benign conditions or were healthy. The sera were analyzed by high throughput ambient ionization technique for mass spectrometry. This gives direct real time analysis of the profile relative metabolites levels in the sera. The profiles were input to a customized functional support vector machine–based machine-learning algorithm for diagnostic classification. Performance was evaluated through a 64-30 split validation test and with a stringent series of leave-one-out cross-validations.

The scientists at Georgia Institute of Technology, (Atlanta, GA, USA), reported that the assay did extremely well in initial tests involving 94 subjects. In addition to being able to generate results using only a drop of blood serum, the test proved to be 100% accurate in distinguishing sera from women with ovarian cancer from normal controls. In addition, it registered neither a single false positive nor a false negative.

John McDonald, Ph.D. the Chief Research Scientist at Georgia Tech., said, "Because ovarian cancer is a disease of relatively low prevalence, it is essential that tests for it be extremely accurate. We believe we may have developed such a test." The results of the study were published online in July 2010 in the journal Cancer Epidemiology, Biomarkers, & Prevention Research. In addition to having a relatively low prevalence, ovarian cancer is also asymptomatic in the early stages. Therefore, if further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.

Related Links:
Georgia Institute of Technology



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic CLIA Analyzer
Shine i6000
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.